Aligos Therapeutics (ALGS) Corporate presentation summary

Development portfolio and financial position

• Pipeline includes pevifoscorvir sodium for chronic HBV, ALG-055009 for MASH/obesity, and ALG-097558 for Covid-19, among others.

• NIH and NIAID awarded $13.8M for Covid-19 protease inhibitor programs.

• Cash, cash equivalents, and investments totaled $77.8M as of 12/31/25, with projected runway into Q4 2026, including a $25M upfront from the Amoytop Greater China license.

Chronic hepatitis B virus (HBV) infection: market and unmet need

• Approximately 254M people globally live with HBV, causing over 1M deaths annually, mainly from cirrhosis and liver cancer.

• HBV is the primary cause of liver cancer, with a market opportunity estimated at $6.2B by 2031.

• Current treatments (NAs and pegylated interferon) are inadequate for many patients, with low rates of functional cure and ongoing disease progression.

Pevifoscorvir sodium: clinical profile and trial results

• Pevifoscorvir sodium is a small molecule CAM-E with picomolar potency, high liver uptake, and a favorable safety profile.

• Demonstrated superior in vitro potency versus first-generation CAM-Es and competitor compounds.

• Phase 1 and 2 studies show profound HBV DNA and RNA reductions, substantial antigen declines, and no viral breakthrough or resistance mutations after 96 weeks.

• Well tolerated in both HBeAg+ and HBeAg- subjects, with manageable ALT/AST elevations and no serious adverse events.

• FDA Fast Track Designation granted; ongoing Phase 2 B-SUPREME study with interim analyses guiding sample size and confirming safety.